Related references
Note: Only part of the references are listed.Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease
Kevin Friede et al.
CLINICAL CHEMISTRY (2017)
Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine
M. Zaiou et al.
CLINICAL GENETICS (2017)
Precision medicine in cardiology
Elliott M. Antman et al.
NATURE REVIEWS CARDIOLOGY (2016)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
J. K. Hicks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis
Lanning Zhang et al.
THROMBOSIS RESEARCH (2015)
A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users
Ruben L. Osnabrugge et al.
GENETICS IN MEDICINE (2015)
Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction
J. P. Depta et al.
PHARMACOGENOMICS JOURNAL (2015)
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Thomas O. Bergmeijer et al.
AMERICAN HEART JOURNAL (2014)
Role of phenotypic and genetic testing in managing clopidogrel therapy
Noel C. Chan et al.
BLOOD (2014)
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel-Treated Patients After Acute Myocardial Infarction
Sharon Cresci et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2014)
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel A Meta-Analysis
Michael J. Sorich et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2014)
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy
Jean-Francois Tanguay et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population
Xiang Xie et al.
PLOS ONE (2013)
Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel
Michel Zabalza et al.
HEART (2012)
Genomic Medicine Genomics and Drug Response
Liewei Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cytochrome P450 2C19☆2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis
F. Sofi et al.
PHARMACOGENOMICS JOURNAL (2011)
Cytochrome P450 2C19 Polymorphism, Suboptimal Reperfusion and All-Cause Mortality in Patients with Acute Myocardial Infarction
Lukasz A. Malek et al.
CARDIOLOGY (2010)
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI A Meta-analysis
Jessica L. Mega et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans
Michael Man et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
Jean-Philippe Collet et al.
LANCET (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
Dietmar Trenk et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
DL Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Genetic polymorphism of cytochrome P4502C19 in healthy Malaysian subjects
YS Yang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
AC Allabi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
JA Goldstein
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
